The University of Southampton
University of Southampton Institutional Repository

Control of pneumococcal disease in the United Kingdom – the start of a new era

Control of pneumococcal disease in the United Kingdom – the start of a new era
Control of pneumococcal disease in the United Kingdom – the start of a new era
In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed for use in
infants and young children in the USA. The subsequent introduction of the vaccine into the
childhood immunization schedule in that country led to a significant decrease in pneumococcal
disease. The vaccine is effective against invasive and non-invasive pneumococcal infection, can be
used in young children as well as adults and, like all conjugate vaccines, provides long-lasting
immunity. Moreover, it reduces the incidence of antibiotic resistance because a number of
resistant serotypes are targeted by the vaccine. Prevnar, also known as Prevenar, has since been
licensed in numerous countries, including the UK.On 8 February 2006, the Departments of Health in
England, Scotland and Wales announced the inclusion of Prevenar in the childhood immunization
schedule. This announcement has important implications for pneumococcal infection, disease
surveillance and immunization policy in the UK.
0022-2615
975-80
Clarke, Stuart C.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Clarke, Stuart C.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17

Clarke, Stuart C. (2006) Control of pneumococcal disease in the United Kingdom – the start of a new era. Journal of Medical Microbiology, 55 (8), 975-80. (doi:10.1099/jmm.0.46579-0).

Record type: Article

Abstract

In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed for use in
infants and young children in the USA. The subsequent introduction of the vaccine into the
childhood immunization schedule in that country led to a significant decrease in pneumococcal
disease. The vaccine is effective against invasive and non-invasive pneumococcal infection, can be
used in young children as well as adults and, like all conjugate vaccines, provides long-lasting
immunity. Moreover, it reduces the incidence of antibiotic resistance because a number of
resistant serotypes are targeted by the vaccine. Prevnar, also known as Prevenar, has since been
licensed in numerous countries, including the UK.On 8 February 2006, the Departments of Health in
England, Scotland and Wales announced the inclusion of Prevenar in the childhood immunization
schedule. This announcement has important implications for pneumococcal infection, disease
surveillance and immunization policy in the UK.

Full text not available from this repository.

More information

Published date: 2006

Identifiers

Local EPrints ID: 152855
URI: https://eprints.soton.ac.uk/id/eprint/152855
ISSN: 0022-2615
PURE UUID: 101167ca-0c39-4111-85a7-1b2aa0b57dff
ORCID for Stuart C. Clarke: ORCID iD orcid.org/0000-0002-7009-1548

Catalogue record

Date deposited: 22 Jun 2010 14:25
Last modified: 06 Jun 2018 12:39

Export record

Altmetrics

Contributors

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×